Background: Individuals with type 2 diabetes (T2D) or the apolipoprotein L1 high-risk (APOL1-HR) genotypes are at increased risk of rapid kidney function decline (RKFD) and kidney failure. We hypothesized that a prognostic test using machine learning integrating blood biomarkers and longitudinal electronic health record (EHR) data would improve risk stratification. Methods: We selected two cohorts from the Mount Sinai BioMe Biobank: T2D (n=871) and African ancestry with APOL1-HR (n=498). We measured plasma tumor necrosis factor receptors (TNFR) 1 and 2 and kidney injury molecule-1 (KIM-1) and used random forest algorithms to integrate biomarker and EHR data to generate a risk score for a composite outcome: RKFD (eGFR decline of ≥5 ml/min per year), or 40% sustained eGFR decline, or kidney failure. We compared performance to a validated clinical model and applied thresholds to assess the utility of the prognostic test (KidneyIntelX) to accurately stratify patients into risk categories. Results: Overall, 23% of those with T2D and 18% of those with APOL1-HR experienced the composite kidney end point over a median follow-up of 4.6 and 5.9 years, respectively. The area under the receiver operator characteristic curve (AUC) of KidneyIntelX was 0.77 (95% CI, 0.75 to 0.79) in T2D, and 0.80 (95% CI, 0.77 to 0.83) in APOL1-HR, outperforming the clinical models (AUC, 0.66 [95% CI, 0.65 to 0.67] and 0.72 [95% CI, 0.71 to 0.73], respectively; P<0.001). The positive predictive values for KidneyIntelX were 62% and 62% versus 46% and 39% for the clinical models (P<0.01) in high-risk (top 15%) stratum for T2D and APOL1-HR, respectively. The negative predictive values for KidneyIntelX were 92% in T2D and 96% for APOL1-HR versus 85% and 93% for the clinical model, respectively (P=0.76 and 0.93, respectively), in low-risk stratum (bottom 50%). Conclusions: In patients with T2D or APOL1-HR, a prognostic test (KidneyIntelX) integrating biomarker levels with longitudinal EHR data significantly improved prediction of a composite kidney end point of RKFD, 40% decline in eGFR, or kidney failure over validated clinical models.
Background: Individuals with type 2 diabetes (T2D) or the apolipoprotein L1 high-risk (APOL1-HR) genotypes are at increased risk of rapid kidney function decline (RKFD) and kidney failure. We hypothesized that a prognostic test using machine learning integrating blood biomarkers and longitudinal electronic health record (EHR) data would improve risk stratification. Methods: We selected two cohorts from the Mount Sinai BioMe Biobank: T2D (n=871) and African ancestry with APOL1-HR (n=498). We measured plasma tumor necrosis factor receptors (TNFR) 1 and 2 and kidney injury molecule-1 (KIM-1) and used random forest algorithms to integrate biomarker and EHR data to generate a risk score for a composite outcome: RKFD (eGFR decline of ≥5 ml/min per year), or 40% sustained eGFR decline, or kidney failure. We compared performance to a validated clinical model and applied thresholds to assess the utility of the prognostic test (KidneyIntelX) to accurately stratify patients into risk categories. Results: Overall, 23% of those with T2D and 18% of those with APOL1-HR experienced the composite kidney end point over a median follow-up of 4.6 and 5.9 years, respectively. The area under the receiver operator characteristic curve (AUC) of KidneyIntelX was 0.77 (95% CI, 0.75 to 0.79) in T2D, and 0.80 (95% CI, 0.77 to 0.83) in APOL1-HR, outperforming the clinical models (AUC, 0.66 [95% CI, 0.65 to 0.67] and 0.72 [95% CI, 0.71 to 0.73], respectively; P<0.001). The positive predictive values for KidneyIntelX were 62% and 62% versus 46% and 39% for the clinical models (P<0.01) in high-risk (top 15%) stratum for T2D and APOL1-HR, respectively. The negative predictive values for KidneyIntelX were 92% in T2D and 96% for APOL1-HR versus 85% and 93% for the clinical model, respectively (P=0.76 and 0.93, respectively), in low-risk stratum (bottom 50%). Conclusions: In patients with T2D or APOL1-HR, a prognostic test (KidneyIntelX) integrating biomarker levels with longitudinal EHR data significantly improved prediction of a composite kidney end point of RKFD, 40% decline in eGFR, or kidney failure over validated clinical models.
Authors: Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: Daniela Dunkler; Peggy Gao; Shun Fu Lee; Georg Heinze; Catherine M Clase; Sheldon Tobe; Koon K Teo; Hertzel Gerstein; Johannes F E Mann; Rainer Oberbauer Journal: Clin J Am Soc Nephrol Date: 2015-07-14 Impact factor: 8.237
Authors: Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Andrew S Levey; Josef Coresh; Ron T Gansevoort; Andrew L Simon; Jian Ying; Gerald J Beck; Christoph Wanner; Jürgen Floege; Philip Kam-Tao Li; Vlado Perkovic; Edward F Vonesh; Tom Greene Journal: J Am Soc Nephrol Date: 2019-07-10 Impact factor: 10.121
Authors: Tomohito Gohda; Monika A Niewczas; Linda H Ficociello; William H Walker; Jan Skupien; Florencia Rosetti; Xavier Cullere; Amanda C Johnson; Gordon Crabtree; Adam M Smiles; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: Anima Singh; Girish Nadkarni; Omri Gottesman; Stephen B Ellis; Erwin P Bottinger; John V Guttag Journal: J Biomed Inform Date: 2014-11-15 Impact factor: 6.317
Authors: Catherine A McCarty; Rex L Chisholm; Christopher G Chute; Iftikhar J Kullo; Gail P Jarvik; Eric B Larson; Rongling Li; Daniel R Masys; Marylyn D Ritchie; Dan M Roden; Jeffery P Struewing; Wendy A Wolf Journal: BMC Med Genomics Date: 2011-01-26 Impact factor: 3.063
Authors: Axel C Carlsson; Lina Nordquist; Tobias E Larsson; Juan-Jesús Carrero; Anders Larsson; Lars Lind; Johan Ärnlöv Journal: Cardiorenal Med Date: 2015-07-31 Impact factor: 2.041
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Shaan Khurshid; Christopher Reeder; Lia X Harrington; Pulkit Singh; Gopal Sarma; Samuel F Friedman; Paolo Di Achille; Nathaniel Diamant; Jonathan W Cunningham; Ashby C Turner; Emily S Lau; Julian S Haimovich; Mostafa A Al-Alusi; Xin Wang; Marcus D R Klarqvist; Jeffrey M Ashburner; Christian Diedrich; Mercedeh Ghadessi; Johanna Mielke; Hanna M Eilken; Alice McElhinney; Andrea Derix; Steven J Atlas; Patrick T Ellinor; Anthony A Philippakis; Christopher D Anderson; Jennifer E Ho; Puneet Batra; Steven A Lubitz Journal: NPJ Digit Med Date: 2022-04-08